TSBX (Turnstone Biologics) Pre-Tax Income : $-75.38 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Turnstone Biologics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Turnstone Biologics's pretax income for the three months ended in Sep. 2024 was $-17.85 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-75.38 Mil. Turnstone Biologics's pretax margin was %.

During the past 3 years, Turnstone Biologics's highest Pretax Margin was 33.27%. The lowest was -287.40%. And the median was -41.87%.

Turnstone Biologics Pre-Tax Income Historical Data

The historical data trend for Turnstone Biologics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turnstone Biologics Pre-Tax Income Chart

Turnstone Biologics Annual Data

Trend

Dec21

Dec22

Dec23

Pre-Tax Income

33.70

-30.69

-55.49

Turnstone Biologics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial							-17.35	-16.62	-19.61	-21.30	-17.85

Competitive Comparison of Turnstone Biologics's Pre-Tax Income

For the Biotechnology subindustry, Turnstone Biologics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Turnstone Biologics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turnstone Biologics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Turnstone Biologics's Pre-Tax Income falls into.

Turnstone Biologics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Turnstone Biologics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-59.032	+	3.546	+	0	+	0	+	0
	=	-55.49

Turnstone Biologics's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-18.368	+	0.52	+	0	+	0	+	0
	=	-17.85

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.38 Mil.

Turnstone Biologics (NAS:TSBX) Pre-Tax Income Explanation

Turnstone Biologics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-17.848	/	0
	=	%

During the past 3 years, Turnstone Biologics's highest Pretax Margin was 33.27%. The lowest was -287.40%. And the median was -41.87%.

Turnstone Biologics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Turnstone Biologics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Turnstone Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turnstone Biologics Corp (NAS:TSBX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.turnstonebio.com

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Executives

Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert J Gould	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Sammy J. Farah	director, officer: President & CEO	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Saryah Azmat	officer: Chief Business Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Venkat Ramanan	officer: Chief Financial Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Campisi Peter Joseph Jr.	officer: Chief Legal Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Vijay Chiruvolu	officer: Int. Chief Technology Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kanya Rajangam	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Versant Ventures V Gp-gp (canada), Inc.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Michael F. Burgess	director, officer: Interim Chief Medical Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stewart Abbot	officer: Chief Scientific Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037